Hyperammonemia treatment sales will grow through 2036, led by sodium phenylbutyrate at 41.2% of the treatment type segment in 2026. The oral route holds a 63.5% share. The market was valued at USD 1.5 billion in 2025, reaching USD 1.6 billion in 2026 and USD 2.5 billion by 2036.